[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG10201509790YA - Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly - Google Patents

Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly

Info

Publication number
SG10201509790YA
SG10201509790YA SG10201509790YA SG10201509790YA SG10201509790YA SG 10201509790Y A SG10201509790Y A SG 10201509790YA SG 10201509790Y A SG10201509790Y A SG 10201509790YA SG 10201509790Y A SG10201509790Y A SG 10201509790YA SG 10201509790Y A SG10201509790Y A SG 10201509790YA
Authority
SG
Singapore
Prior art keywords
antigen
binding
molecule capable
binding molecule
molecules repeatedly
Prior art date
Application number
SG10201509790YA
Inventor
Tomoyuki Igawa
Shinya Ishii
Miho Funaki
Naoka Hironiwa
Atsuhiko Maeda
Junichi Nezu
Yoshinao Ruike
Takeshi Baba
Shun Shimizu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG10201509790YA publication Critical patent/SG10201509790YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
SG10201509790YA 2010-11-30 2011-11-30 Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly SG10201509790YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010266121 2010-11-30
JP2011217886 2011-09-30

Publications (1)

Publication Number Publication Date
SG10201509790YA true SG10201509790YA (en) 2015-12-30

Family

ID=46171919

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201509790YA SG10201509790YA (en) 2010-11-30 2011-11-30 Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
SG2013041611A SG190727A1 (en) 2010-11-30 2011-11-30 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013041611A SG190727A1 (en) 2010-11-30 2011-11-30 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Country Status (14)

Country Link
US (3) US20140234340A1 (en)
EP (2) EP2647706B1 (en)
JP (6) JP6030452B2 (en)
KR (2) KR102568454B1 (en)
CN (3) CN107973851A (en)
AU (1) AU2011337704B2 (en)
BR (1) BR112013013354A2 (en)
CA (1) CA2819356C (en)
HK (2) HK1251592A1 (en)
MX (2) MX365235B (en)
RU (3) RU2658504C9 (en)
SG (2) SG10201509790YA (en)
TW (5) TWI812066B (en)
WO (1) WO2012073992A1 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4342995A3 (en) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
PE20090711A1 (en) 2007-09-26 2009-07-15 Chugai Pharmaceutical Co Ltd CONSTANT REGION OF MUTANT ANTIBODY
RU2510400C9 (en) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Modification method of isoelectric point of antibody by means of amino-acid replacements in cdr
KR102051275B1 (en) 2008-04-11 2019-12-04 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
TWI812066B (en) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 Antibody having calcium-dependent antigen-binding ability
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
KR102049122B1 (en) 2011-06-30 2019-11-26 추가이 세이야쿠 가부시키가이샤 Heterodimerized polypeptide
TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
JP6284766B2 (en) * 2011-09-30 2018-02-28 中外製薬株式会社 Ion concentration-dependent binding molecule library
KR102239138B1 (en) 2011-09-30 2021-04-12 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule inducing immune response to target antigen
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
EP2765192A4 (en) * 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
BR112014013081A2 (en) * 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha drug-containing cell vehicle for formation of an immune complex
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
TWI766939B (en) 2012-05-30 2022-06-11 日商中外製藥股份有限公司 target tissue-specific antigen binding molecule
ES2856272T3 (en) * 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule to remove aggregated antigens
MX371442B (en) 2012-08-24 2020-01-30 Chugai Pharmaceutical Co Ltd Fcyriib-specific fc region variant.
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
JP6280300B2 (en) * 2012-08-24 2018-02-14 中外製薬株式会社 Brain disease treatment
TWI693073B (en) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients
WO2015097928A1 (en) * 2013-12-24 2015-07-02 中外製薬株式会社 Method for measuring soluble gpc3 protein
DK2940135T5 (en) 2012-12-27 2021-09-20 Chugai Pharmaceutical Co Ltd Heterodimerized polypeptide
KR102065112B1 (en) * 2013-02-28 2020-01-10 삼성전자주식회사 A method to screen antibodies with high selectivity
CN113621057A (en) 2013-04-02 2021-11-09 中外制药株式会社 Fc region variants
MX2016003616A (en) 2013-09-27 2016-07-21 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer.
KR20240134226A (en) 2013-12-04 2024-09-06 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
KR102409014B1 (en) 2014-05-08 2022-06-14 추가이 세이야쿠 가부시키가이샤 Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
KR101624702B1 (en) * 2014-08-01 2016-05-27 한국과학기술원 Novel polypeptide binding with human complement component 5a and Uses Thereof
KR101838645B1 (en) 2014-12-19 2018-03-14 추가이 세이야쿠 가부시키가이샤 Anti-c5 antibodies and methods of use
TWI779010B (en) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
CN112142844A (en) 2015-02-05 2020-12-29 中外制药株式会社 Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof
TWI805046B (en) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Use of IL-6 receptor antibody for preparing pharmaceutical composition
WO2017002934A1 (en) 2015-07-01 2017-01-05 中外製薬株式会社 Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
PL3347377T3 (en) * 2015-09-09 2021-07-19 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
AR105634A1 (en) 2015-09-18 2017-10-25 Chugai Pharmaceutical Co Ltd ANTIBODIES THAT JOIN IL 8 AND ITS USES
KR20180057657A (en) 2015-09-23 2018-05-30 브리스톨-마이어스 스큅 컴퍼니 Glypicane-3-linked fibronectin-based scaffold molecules
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN109310755A (en) * 2016-02-02 2019-02-05 卡德门企业有限公司 The bispecific binding protein of PD-L1 and KDR
CN110072887A (en) 2016-08-02 2019-07-30 威特拉公司 Engineered polypeptide and its application
KR102538749B1 (en) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Composition for prophylaxis or treatment of il-8 related diseases
EP3497120A1 (en) * 2016-08-12 2019-06-19 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
JP7205995B2 (en) * 2017-03-29 2023-01-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antigen-binding molecules for co-stimulatory TNF receptors
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
JP7185884B2 (en) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター METHOD FOR PREDICTING AND DETERMINING THERAPEUTIC EFFECT OF IL-6 AND NEUTROPHIL-RELATED DISEASE
MX2019014576A (en) * 2017-06-05 2020-07-29 Janssen Biotech Inc Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations.
CN116271012A (en) 2017-07-27 2023-06-23 瑞颂医药公司 High concentration anti-C5 antibody formulations
WO2019060918A1 (en) * 2017-09-25 2019-03-28 University Of Florida Research Foundation, Incorporated Immuoassays for detection of ran proteins
KR20200070355A (en) 2017-10-26 2020-06-17 알렉시온 파마슈티칼스, 인코포레이티드 Dosage and administration of anti-C5 antibodies for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS)
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
EP3704148A1 (en) 2017-10-31 2020-09-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
CN112119090B (en) 2018-03-15 2023-01-13 中外制药株式会社 Anti-dengue virus antibodies cross-reactive to Zika virus and methods of use
SG10202106830VA (en) 2018-08-10 2021-08-30 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
CN109374884B (en) * 2018-12-24 2021-10-22 四川沃文特生物技术有限公司 PCT concentration detection kit and preparation method thereof
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
BR112021020204A2 (en) 2019-04-10 2021-12-07 Chugai Pharmaceutical Co Ltd Method for purifying antibody with modified fc region
CN110467672B (en) * 2019-08-20 2020-05-05 江苏省疾病预防控制中心(江苏省公共卫生研究院) Fully human monoclonal neutralizing antibody aiming at SFTSV and application thereof
WO2021122733A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
WO2021131021A1 (en) 2019-12-27 2021-07-01 中外製薬株式会社 Anti-ctla-4 antibody and use thereof
TW202144395A (en) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 Anti-CD137 antigen-binding molecule for use in cancer treatment
WO2022015934A2 (en) * 2020-07-15 2022-01-20 The Johns Hopkins Universtiy Comprehensive analysis of anti-allergen antibodies using phage display
JPWO2022044248A1 (en) 2020-08-28 2022-03-03
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
AR125344A1 (en) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd ANTI-C1S ANTIBODY
WO2022235960A1 (en) * 2021-05-06 2022-11-10 Sorrento Therapeutics, Inc. Neutralizing antibodies that bind variant sars-cov-2 spike proteins
KR20240021859A (en) 2021-06-18 2024-02-19 에프. 호프만-라 로슈 아게 Bispecific anti-CCL2 antibody
AU2022299846B2 (en) 2021-06-25 2024-08-15 Chugai Seiyaku Kabushiki Kaisha Anti–ctla-4 antibody
WO2022270612A1 (en) 2021-06-25 2022-12-29 中外製薬株式会社 Use of anti-ctla-4 antibody
CN113563480B (en) * 2021-07-12 2023-04-28 成都维瑾柏鳌生物医药科技有限公司 CLD protein mutant and application thereof
WO2023013618A1 (en) * 2021-08-02 2023-02-09 国立研究開発法人国立長寿医療研究センター Human astrovirus infection receptor and application of same
CN115873111B (en) * 2022-12-19 2024-06-07 华润生物医药有限公司 CLDN18.2 antibody and application thereof

Family Cites Families (493)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4961501U (en) 1972-09-06 1974-05-30
JPS525973Y2 (en) 1973-09-06 1977-02-08
FR2416931A1 (en) 1978-02-10 1979-09-07 Lambiotte Usines NON-POLLUTING WOOD CARBONIZATION PROCESS
US4769320A (en) 1982-07-27 1988-09-06 New England Medical Center Hospitals, Inc. Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
ES521371A0 (en) 1982-04-12 1984-05-16 Hybritech Inc A PROCEDURE FOR THE PURIFICATION OF AN ANTIBODY.
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6088703U (en) 1983-11-24 1985-06-18 リョービ株式会社 Cutting waste discharge device for automatic planing machine
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH06104071B2 (en) * 1986-08-24 1994-12-21 財団法人化学及血清療法研究所 Factor IX Monoclonal antibody specific for conformation
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
JPH01144991A (en) 1987-12-02 1989-06-07 Kagaku Oyobi Ketsusei Riyouhou Kenkyusho Purification of blood coagulation factor viii
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US5126250A (en) 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
AR242986A1 (en) 1988-09-28 1993-06-30 Lilly Co Eli A method for reducing the heterogeneous nature of antibodies secreted by cells which produce antibodies.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2006684C (en) 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
JPH0636741B2 (en) * 1989-11-08 1994-05-18 帝人株式会社 Method for separating human protein C
EP0515571B1 (en) 1990-02-16 1998-12-02 Boston Biomedical Research Institute Hybrid reagents capable of selectively releasing molecules into cells
US5130129A (en) 1990-03-06 1992-07-14 The Regents Of The University Of California Method for enhancing antibody transport through capillary barriers
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE300615T1 (en) 1990-08-29 2005-08-15 Genpharm Int TRANSGENIC MICE CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5468634A (en) 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
DE69229477T2 (en) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methods for the production of humanized antibodies
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
JPH07503132A (en) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド Transgenic non-human animals capable of producing xenoantibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
DE69333823T2 (en) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn METHOD FOR PRODUCING MEMBERS OF SPECIFIC BINDING SAVINGS
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
BR9204244A (en) 1992-10-26 1994-05-03 Cofap Gray cast iron
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
EP0671951A4 (en) 1992-12-01 1997-05-21 Protein Design Labs Inc Humanized antibodies reactive with l-selectin.
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
DE69432815T2 (en) 1993-03-19 2003-12-11 The Johns Hopkins University School Of Medicine, Baltimore GROWTH FACTOR-8
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
FR2707189B1 (en) 1993-07-09 1995-10-13 Gradient Ass Method for treating combustion residues and installation for implementing said method.
GB9314271D0 (en) 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
DE4419399C1 (en) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Process for the preparation of heterologous bispecific antibodies
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
ATE198712T1 (en) 1994-07-11 2001-02-15 Univ Texas METHODS AND COMPOSITIONS FOR THE SPECIFIC COAGULATION OF TUMOR VESSELS
CN1156460A (en) 1994-07-13 1997-08-06 中外制药株式会社 Reconstructed hyman antibody against human interleukin-8
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
TW416960B (en) 1994-07-13 2001-01-01 Chugai Pharmaceutical Co Ltd Reshaped human antibody to human interleukin-8
JP3865418B2 (en) 1994-07-13 2007-01-10 中外製薬株式会社 Reconstituted human antibody against human interleukin-8
US6048972A (en) 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
KR100306517B1 (en) 1994-10-07 2001-11-30 나가야마 오사무 Chronic rheumatoid arthritis treatment with active ingredients of interleukin-6 antagonists
CZ296979B6 (en) 1994-10-21 2006-08-16 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention or treatment of Castleman's disease
DE19500911A1 (en) 1995-01-13 1996-07-18 Basf Ag Substituted 2-phenylpyridines
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5830478A (en) 1995-06-07 1998-11-03 Boston Biomedical Research Institute Method for delivering functional domains of diphtheria toxin to a cellular target
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
DE69731289D1 (en) 1996-03-18 2004-11-25 Univ Texas IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES
ZA976326B (en) 1996-07-19 1998-02-03 Amgen Inc Analogs of cationic proteins.
US7247302B1 (en) 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
ES2300113T3 (en) 1996-08-02 2008-06-01 Bristol-Myers Squibb Company A PROCEDURE FOR INHIBITING TOXICITY INDUCED BY IMMUNOGLOBULINS RESULTING FROM THE USE OF IMMUNOGLOBULINS IN THERAPY AND IN VIVO DIAGNOSIS.
US6025158A (en) 1997-02-21 2000-02-15 Genentech, Inc. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2284271C (en) 1997-03-21 2012-05-08 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient
WO1998046257A1 (en) 1997-04-17 1998-10-22 Amgen Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
DK0979281T3 (en) 1997-05-02 2005-11-21 Genentech Inc Process for the preparation of multispecific antibodies with heteromultimers and common components
CN1068524C (en) 1997-06-23 2001-07-18 叶庆炜 Process for preparing medicine for curing intractable psoriasis
US5980893A (en) 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
KR20090068385A (en) 1997-08-15 2009-06-26 츄가이 세이야꾸 가부시키가이샤 Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
RU2221809C2 (en) 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Method for preparing natural humanized antibody
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
EP1069898B1 (en) 1998-03-17 2004-05-12 MARGOLIN, Solomon B. Topical antiseptic compositions and methods
DE69937994T2 (en) 1998-03-17 2008-12-24 Chugai Seiyaku K.K. PROPHYLACTIC OR THERAPEUTIC AGENTS AGAINST INFLAMMATORY DISEASES OF THE DIGESTIVE STRUCTURE CONTAINED ANTAGONISTIC IL-6 RECEPTOR ANTIBODIES
AU3369999A (en) 1998-04-02 1999-10-25 Genentech Inc. Antibody variants and fragments thereof
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (en) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド Generation of modified molecules with increased serum half-life
US6475718B2 (en) * 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
JP2002531466A (en) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド Humanized antibodies to gamma interferon
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MX353234B (en) 1999-01-15 2018-01-08 Genentech Inc Polypeptide variants with altered effector function.
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
AU2006225302B2 (en) 1999-03-25 2010-08-12 AbbVie Deutschland GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
PT1914244E (en) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Method of modulating the activity of functional immune molecules
EP1188830B1 (en) 1999-06-02 2010-01-20 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein ,nr10
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040058393A1 (en) 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
CZ20023913A3 (en) 2000-05-03 2003-09-17 Munich Biotech Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
JP4902087B2 (en) 2000-06-16 2012-03-21 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Antibodies that immunospecifically bind to BLyS
AU2011244851A1 (en) 2000-07-27 2011-11-24 The John Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
DK1325033T3 (en) 2000-10-10 2010-04-06 Genentech Inc Inhibition of complement C5 activation for the treatment and prevention of delayed xenographic or acute vascular rejection
EP1356075A4 (en) 2000-10-16 2005-04-13 Compound Therapeutics Inc Protein scaffolds for antibody mimics and other binding proteins
DK1334731T3 (en) 2000-10-25 2008-05-26 Chugai Pharmaceutical Co Ltd Preventive or therapeutic agent for psoriasis comprising anti-IL-6 receptor antibody as active ingredient
AU2000279625A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
DK1355919T3 (en) 2000-12-12 2011-03-14 Medimmune Llc Molecules with longer half-lives, compositions and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
MXPA03009390A (en) 2001-04-13 2004-01-29 Biogen Inc Antibodies to vla-1.
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE60228721D1 (en) 2001-06-22 2008-10-16 Chugai Pharmaceutical Co Ltd Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
MX342385B (en) 2001-08-17 2016-09-27 Genentech Inc Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b.
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
NZ533223A (en) 2001-11-14 2007-04-27 Centocor Inc Anti-il-6 antibodies, compositions, methods and uses
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
EP3960855A1 (en) 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
PL211833B1 (en) 2002-01-18 2012-06-29 Zymogenetics Inc Isolated polypeptide, fusion protein, isolated polynucleotide molecule, expression vector, cultured cell, a method for obtaining the polypeptide, a method for obtaining an antibody, an antibody, an antibody or a fragment thereof, the use of the antibody, a method for detecting the presence of a polypeptide, a method for inhibition the hematopoietic cells proliferation or differentiation, the use of a polypeptide, a method for spreading of hematopoietic cells, a method for detecting RNA presence, a method of killing cancer cells in vitro or in vivo, the use of a polypeptide, the use of a polypeptide, antagonist and a method for detecting infection in a patient
ATE547430T1 (en) 2002-01-18 2012-03-15 Zymogenetics Inc MULTIMERS OF THE CYTOKINE RECEPTOR ZCYTOR17
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20070122406A1 (en) 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003107218A1 (en) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 Interaction predicting device
WO2003102580A1 (en) 2002-05-31 2003-12-11 Biacore Ab Method of coupling binding agents to a substrate surface
JP3991280B2 (en) 2002-06-05 2007-10-17 中外製薬株式会社 Antibody production method
WO2003105757A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
EP2107116A3 (en) 2002-06-12 2009-12-09 Genencor International, Inc. Methods for improving a binding characteristic of a molecule
ITMI20021527A1 (en) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
WO2004022595A1 (en) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
MXPA05002968A (en) 2002-09-16 2005-09-08 Univ Johns Hopkins Metalloprotease activation of myostatin, and methods of modulating myostatin activity.
KR100980065B1 (en) 2002-09-27 2010-09-03 젠코어 인코포레이티드 Optimized fc variants and methods for their generation
CA2502904C (en) 2002-10-15 2013-05-28 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
EP1590364B1 (en) 2002-12-16 2011-10-05 Genmab A/S Human monoclonal antibodies against interleukin 8 (il-8)
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
ES2897506T3 (en) 2003-01-09 2022-03-01 Macrogenics Inc Identification and modification of antibodies with variant Fc regions and methods of using them
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
WO2004076485A1 (en) 2003-02-28 2004-09-10 Lonza Biologics Plc. Antibody purification by protein a and ion exchange chromatography
CA2517396A1 (en) 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
CN1756564A (en) 2003-03-04 2006-04-05 亚历森制药有限公司 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
CN102690350A (en) 2003-03-24 2012-09-26 津莫吉尼蒂克斯公司 anti-IL-22 RA antibodies and binding partners and methods of use in inflammation
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2766627C (en) 2003-05-02 2019-12-03 Xencor, Inc. Optimized fc variants and methods for their generation
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
JP5110877B2 (en) 2003-06-02 2012-12-26 ワイス・エルエルシー Use of myostatin (GDF8) inhibitors in combination with corticosteroids to treat neuromuscular disorders
WO2004113387A2 (en) 2003-06-24 2004-12-29 Merck Patent Gmbh Tumour necrosis factor receptor molecules with reduced immunogenicity
WO2005023193A2 (en) 2003-09-04 2005-03-17 Interleukin Genetics, Inc. Methods of treating endometriosis
WO2005027966A2 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
WO2005037315A1 (en) 2003-10-17 2005-04-28 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for mesothelioma
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US7820800B2 (en) 2003-11-05 2010-10-26 Ares Trading S.A. Process for the purification of IL-18 binding protein
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US20050142133A1 (en) 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP1691837B1 (en) 2003-12-10 2012-06-20 Medarex, Inc. Ip-10 antibodies and their uses
AR048210A1 (en) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd A PREVENTIVE AGENT FOR VASCULITIS.
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
CN1902221A (en) 2003-12-31 2007-01-24 先灵-普劳有限公司 Neutralizing epitope-based growth enhancing vaccine
US20080089892A1 (en) 2004-01-12 2008-04-17 Eli Lilly And Co. Fc Region Variants
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
JP2008505054A (en) 2004-02-11 2008-02-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Methods of treating osteoarthritis with IL-6 antagonists
BRPI0508716A (en) 2004-03-23 2007-08-07 Lilly Co Eli monoclonal antibody, process for producing the same, pharmaceutical composition, and use of a monoclonal antibody
KR20070035482A (en) 2004-03-24 2007-03-30 추가이 세이야쿠 가부시키가이샤 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
AR048335A1 (en) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENTS FOR INTERNAL EAR DISORDERS CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT
WO2005090405A1 (en) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha Subtype of humanized antibody against interleukin-6 receptor
US8435517B2 (en) 2008-09-17 2013-05-07 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005115452A2 (en) 2004-04-16 2005-12-08 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
JP2008503217A (en) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド Novel antigen-binding polypeptides and their use
EP1773391A4 (en) 2004-06-25 2009-01-21 Medimmune Inc Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
ES2372503T3 (en) 2004-07-06 2012-01-20 Bioren, Inc. REVISED MUTAGENESIS TO DEVELOP ALTERED POLYPEPTIDES WITH POTENTIATED PROPERTIES.
KR101413402B1 (en) 2004-07-09 2014-06-27 츄가이 세이야꾸 가부시키가이샤 Anti-Glypican 3 Antibody
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
PL2471813T3 (en) 2004-07-15 2015-09-30 Xencor Inc Optimized Fc variants
EP1776384B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant fc regions
US7659374B2 (en) 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
WO2009006338A1 (en) 2007-06-29 2009-01-08 Quest Diagnostics Investments Incorporated Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
CA2585043A1 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
AU2005302453A1 (en) 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
RU2412200C2 (en) 2004-11-12 2011-02-20 Ксенкор, Инк. Fc-VERSIONS WITH CHANGED BINDING WITH FcRn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006053301A2 (en) 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
EP2208783A1 (en) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
WO2006066598A2 (en) 2004-12-23 2006-06-29 Novo Nordisk A/S Antibody binding affinity ligands
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
AU2005321017B2 (en) 2004-12-28 2011-02-24 Innate Pharma S.A. Monoclonal antibodies against NKG2A
CA2595169A1 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
AU2006214404B2 (en) 2005-02-14 2012-03-08 Bristol-Myers Squibb Company Methods of treating skin disorders using an IL-31RA antagonist
WO2006102095A2 (en) 2005-03-18 2006-09-28 Medimmune, Inc. Framework-shuffling of antibodies
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP5057967B2 (en) 2005-03-31 2012-10-24 中外製薬株式会社 sc (Fv) 2 structural isomer
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
SI1876236T1 (en) 2005-04-08 2014-11-28 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
US8604174B2 (en) 2005-04-20 2013-12-10 Amgen Inc. High affinity fully human monoclonal antibodies to interleukin-8
ZA200709291B (en) 2005-04-25 2009-01-28 Pfizer Antibodies to myostatin
AU2006239851B2 (en) 2005-04-26 2011-06-16 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PE20061324A1 (en) 2005-04-29 2007-01-15 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
FR2888850B1 (en) 2005-07-22 2013-01-11 Pf Medicament NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
PT2573114T (en) 2005-08-10 2016-07-13 Macrogenics Inc Identification and engineering of antibodies with variant fc regions and methods of using same
BRPI0614893A2 (en) 2005-08-19 2010-03-30 Wyeth Corp isolated antibody capable of binding gdf-8, isolated polynucleotide, host cell, vector, method for producing an in vitro antibody to diagnose or detect if a patient is suffering from a disorder associated with gdf-8 to monitor the severity of an associated disorder gdf-8 and to predict the possibility that a patient will develop a disorder associated with gdf-8, isolated and purified antibody, pharmaceutical composition for treating, ameliorating and / or preventing a disorder associated with gdf-8, and uses of an effective amount of antibody and polynucleotide
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
BRPI0616923A2 (en) 2005-10-06 2011-07-05 Lilly Co Eli monoclonal antibodies, their uses and pharmaceutical composition
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
AU2006305119B2 (en) 2005-10-21 2012-12-20 Chugai Seiyaku Kabushiki Kaisha Agents for treating cardiopathy
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
WO2007061029A1 (en) 2005-11-25 2007-05-31 Keio University Therapeutic agent for prostate cancer
CA2631212A1 (en) 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
AU2006326283B2 (en) 2005-12-12 2012-01-19 Ac Immune S.A. Therapeutic vaccine
WO2007074880A1 (en) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilizing preparation
LT3219328T (en) 2005-12-29 2020-09-10 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, method and uses
JP2009528264A (en) 2006-01-10 2009-08-06 ザイモジェネティクス，インコーポレイティド Methods for treating pain and inflammation in neural tissue using IL-31 antagonists
CN101370521A (en) 2006-01-27 2009-02-18 学校法人庆应义塾 Remedy for disease associated with choroidal angiogenesis
KR20080098504A (en) 2006-02-03 2008-11-10 메디뮨 엘엘씨 Protein formulations
US20070190056A1 (en) 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
JP4179517B2 (en) 2006-02-21 2008-11-12 プロテノバ株式会社 Immunoglobulin affinity ligand
US8674073B2 (en) 2006-02-21 2014-03-18 Protenova Co., Ltd. Immunoglobulin affinity ligand
CN101437501B (en) 2006-03-02 2012-09-05 阿莱克申药物公司 Prolongation of survival of an allograft by inhibiting complement activity
HUE026496T2 (en) 2006-03-08 2016-06-28 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
GEP20135917B (en) 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
WO2007108559A1 (en) 2006-03-23 2007-09-27 Kirin Pharma Kabushiki Kaisha Agonistic antibody directed against human thrombopoietin receptor
US7612178B2 (en) 2006-03-28 2009-11-03 Biogen Idec Ma Inc Anti-IGF-1R antibodies and uses thereof
WO2007114325A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP4342995A3 (en) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
NZ572565A (en) 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
PL2041177T3 (en) 2006-06-02 2012-09-28 Regeneron Pharma High affinity antibodies to human il-6 receptor
RU2511406C2 (en) 2006-06-08 2014-04-10 Чугаи Сейяку Кабусики Кайся Preventive and therapeutic agent for inflammatory disease
ES2415655T3 (en) 2006-06-15 2013-07-26 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine-like compounds
CL2007001829A1 (en) 2006-06-23 2008-01-25 Smithkline Beecham Corp N- [4-Chloro-2-hydroxy-3- (piperazine-1-sulfonyl) phenyl] -n- (2-chloro-3-fluorophenyl) urea P-toluenesulfonate; preparation process; pharmaceutical composition; pharmaceutical combination; and use in the treatment of a disease mediated by chemokine il-8, such as asthma and epoc.
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
US20120189640A1 (en) 2006-08-02 2012-07-26 The Uab Research Foundation Methods and Compositions Related to Soluble Monoclonal Variable Lymphocyte Receptors of Defined Antigen Specificity
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
DK2383297T5 (en) 2006-08-14 2022-07-04 Xencor Inc Optimized antibodies directed against CD19
JP5058261B2 (en) 2006-09-05 2012-10-24 イーライ リリー アンド カンパニー Anti-myostatin antibody
PL2066349T3 (en) 2006-09-08 2012-09-28 Medimmune Llc Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
EP2695896B1 (en) 2006-10-06 2018-08-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Prevention of tissue ischemia, related methods and compositions
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008121160A2 (en) 2006-11-21 2008-10-09 Xencor, Inc. Optimized antibodies that target cd5
CN100455598C (en) 2006-11-29 2009-01-28 中国抗体制药有限公司 Antibody of anti human CD20 from human resources functionally, and application
DK2426143T3 (en) 2007-01-05 2017-09-11 Univ Zuerich Process for providing disease-specific binding molecules and targets
WO2008091798A2 (en) 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
MX2009007830A (en) 2007-01-23 2009-10-07 Univ Shinshu Chronic rejection inhibitor.
AU2008207898B2 (en) 2007-01-23 2012-05-03 Xencor, Inc Optimized CD40 antibodies and methods of using the same
EP2107115A1 (en) 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2008098115A2 (en) 2007-02-07 2008-08-14 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
EP2069404B1 (en) 2007-02-14 2011-01-05 Vaccinex, Inc. Humanized anti-cd100 antibodies
KR101520110B1 (en) 2007-02-23 2015-05-18 머크 샤프 앤드 돔 코포레이션 Engineered Anti-IL-23p19 Antibodies
US20100184959A1 (en) 2007-03-19 2010-07-22 Medimmune Limited Polypeptide Variants
AU2008229141B2 (en) 2007-03-20 2013-02-07 Eli Lilly And Company Anti-sclerostin antibodies
AU2008228247A1 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
CL2008001071A1 (en) 2007-04-17 2009-05-22 Smithkline Beecham Corp Method to obtain penta-specific antibody against human il-8 / cxcl8, gro-alpha / cxcl1, gro-beta / cxcl2), gro-gamma / cxcl3 and ena-78 / cxcl5; penta-specific antibody; production process of the same; vector, hybridoma or cella that comprises it; pharmaceutical composition; use to treat copd, other diseases.
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP3392273A1 (en) 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
US20100291023A1 (en) 2007-05-31 2010-11-18 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
PL2158315T3 (en) 2007-06-25 2016-10-31 Methods of modifying antibodies, and modified antibodies with improved functional properties
BRPI0813287A2 (en) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit PLANNING AND OPTIMIZATION BASED ON THE SEQUENCE OF SINGLE CHAIN ANTIBODIES
JP5424330B2 (en) 2007-07-26 2014-02-26 国立大学法人大阪大学 A therapeutic agent for ocular inflammatory diseases comprising an interleukin 6 receptor inhibitor as an active ingredient
US20110105724A1 (en) 2007-08-16 2011-05-05 Stephanie Jane Clegg Novel compounds
CN101842116A (en) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 Compositions that bind multiple epitopes of IGF-1R
AU2008295506A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-IGF-1R antibodies and uses thereof
EP2031064A1 (en) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Method for increasing protein titres
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
PE20090711A1 (en) 2007-09-26 2009-07-15 Chugai Pharmaceutical Co Ltd CONSTANT REGION OF MUTANT ANTIBODY
WO2009041734A1 (en) 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. Agonistic antibody against human thrombopoietin receptor
RU2510400C9 (en) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Modification method of isoelectric point of antibody by means of amino-acid replacements in cdr
AR068564A1 (en) 2007-09-26 2009-11-18 Chugai Pharmaceutical Co Ltd ANTI-RECEIVER ANTIBODY OF IL-6 (INTERLEUQUINA 6)
CN101809162B (en) 2007-09-28 2013-06-05 中外制药株式会社 Anti-glypican-3 antibody having improved kinetics in plasma
KR100888133B1 (en) 2007-10-02 2009-03-13 에스케이에너지 주식회사 Method of preparing multicomponent bismuth molybdate catalysts comprising four metal components and method of preparing 1,3-butadiene using said catalysts
BRPI0817482B8 (en) 2007-10-02 2021-05-25 Chugai Pharmaceutical Co Ltd use of an interleukin-6 (il-6) receptor antibody in the treatment of graft versus host disease (gvhd)
AR068767A1 (en) 2007-10-12 2009-12-02 Novartis Ag ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
AU2008314687A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying Fc-fusion proteins
PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
AU2008321835B2 (en) 2007-11-15 2014-11-20 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
ES2585480T3 (en) 2007-12-05 2016-10-06 Chugai Seiyaku Kabushiki Kaisha Anti-NR10 antibody and use thereof
RU2596397C2 (en) 2007-12-05 2016-09-10 Чугаи Сейяку Кабусики Кайся Therapeutic agent for itching
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
CN105418762B (en) 2007-12-26 2019-11-05 Xencor公司 With the Fc variant of FcRn Binding change
WO2009089846A1 (en) 2008-01-18 2009-07-23 Stichting Sanquin Bloedvoorziening Methods for increasing the therapeutic efficacy of immunoglobulin g class 3 (igg3) antibodies
EP2238156B1 (en) 2008-01-29 2014-10-01 Ablynx N.V. Methods to stabilize proteins and polypeptides
KR102051275B1 (en) 2008-04-11 2019-12-04 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
AU2015227424A1 (en) 2008-04-11 2015-10-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
MX2010012437A (en) 2008-05-14 2011-06-01 Agriculture Victoria Serv Pty Use of angiogenin or angiogenin agonists for treating diseases and disorders.
US20110081347A1 (en) 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
CN104906581A (en) 2008-06-05 2015-09-16 国立研究开发法人国立癌症研究中心 Neuroinvasion inhibitor
PE20110225A1 (en) 2008-08-05 2011-04-05 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C5
JP5028372B2 (en) 2008-09-26 2012-09-19 京セラドキュメントソリューションズ株式会社 Image processing apparatus, image processing method, and image processing program
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5229888B2 (en) 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 Protein A mutant protein and antibody capture agent with improved easy dissociation in weakly acidic region
ES2828721T3 (en) 2008-10-14 2021-05-27 Genentech Inc Immunoglobulin variants and their uses
NZ614351A (en) 2008-11-10 2015-05-29 Alexion Pharma Inc Methods and compositions for treating complement-associated disorders
WO2010058860A1 (en) 2008-11-18 2010-05-27 株式会社シノテスト Measurement method and measurement reagent for c-reactive protein in sample
CN103861106B (en) 2008-11-25 2017-03-22 奥尔德生物制药公司 Antagonists of IL-6 to raise albumin and/or lower CRP
AR074777A1 (en) 2008-12-19 2011-02-09 Glaxo Group Ltd PROTEINS OF UNION TO ANTIGEN
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
CA2750533A1 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
US20100292443A1 (en) 2009-02-26 2010-11-18 Sabbadini Roger A Humanized platelet activating factor antibody design using anti-lipid antibody templates
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
TWI682995B (en) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 Antibody constant region alteration
SG10201703707YA (en) 2009-03-19 2017-06-29 Chugai Pharmaceutical Co Ltd Pharmaceutical formulation containing improved antibody molecules
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
AU2010201495B2 (en) 2009-04-16 2012-04-12 Accenture Global Services Limited Touchpoint customization system
MX2011012136A (en) 2009-05-15 2012-04-10 Chugai Pharmaceutical Co Ltd Anti-axl antibody.
US20120303083A1 (en) 2009-05-26 2012-11-29 The Johns Hopkins University Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US20110002931A1 (en) 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
US8945511B2 (en) 2009-06-25 2015-02-03 Paul Weinberger Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
RU2595409C2 (en) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Anti-gitr antibodies
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5734988B2 (en) 2009-10-06 2015-06-17 メディミューン リミテド RSV specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
PL2486141T3 (en) 2009-10-07 2018-07-31 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US8734798B2 (en) 2009-10-27 2014-05-27 Ucb Pharma S.A. Function modifying NAv 1.7 antibodies
CN101875696B (en) 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 Antibody, and preparation method and application thereof
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
AU2010336277B2 (en) 2009-12-25 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Polypeptide modification method for purifying polypeptide multimers
CN102971342B (en) 2010-01-28 2016-08-03 Ab生物科学公司 The new antibodies that affinity reduces and the method preparing described antibody
JP2013518606A (en) 2010-02-09 2013-05-23 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New use
RS61136B1 (en) 2010-02-19 2020-12-31 Xencor Inc Novel ctla4-ig immunoadhesins
KR20130009784A (en) 2010-03-01 2013-01-23 알렉시온 파마슈티칼스, 인코포레이티드 Methods and compositions for treating degos' disease
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
JP2011184418A (en) 2010-03-11 2011-09-22 Tokyo Institute Of Technology Affinity variable antibody
SA111320266B1 (en) 2010-03-11 2015-06-21 رينات نيوروساينس كوربوريشن Antibodies with pH Dependent Antigen Binding
TW201206466A (en) 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
TWI667346B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
CN104402997A (en) 2010-04-30 2015-03-11 阿雷克森制药公司 Antibodies having reduced immunogenicity in a human
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
WO2011149046A1 (en) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター Therapeutic agent for pancreatic cancer
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
JP5953303B2 (en) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド Antibodies with modified isoelectric points
WO2012024242A1 (en) 2010-08-16 2012-02-23 Amgen Inc. Antibodies that bind myostatin, compositions and methods
MX349622B (en) 2010-09-08 2017-08-07 Halozyme Inc Methods for assessing and identifying or evolving conditionally active therapeutic proteins.
CN103261222B (en) 2010-09-10 2017-07-28 医疗免疫有限公司 Antibody derivatives
EP2638067A2 (en) 2010-11-08 2013-09-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
TWI812066B (en) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 Antibody having calcium-dependent antigen-binding ability
CA2822288A1 (en) 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
JP6043629B2 (en) 2011-01-07 2016-12-14 中外製薬株式会社 Methods for improving antibody physical properties
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
WO2012132067A1 (en) 2011-03-30 2012-10-04 中外製薬株式会社 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
MX2013010011A (en) 2011-03-01 2014-10-24 Amgen Inc Sclerostin and dkk-1 bispecific binding agents.
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
LT3404041T (en) 2011-04-19 2020-08-25 Amgen Inc. Method for treating osteoporosis
JP6125489B2 (en) 2011-04-29 2017-05-10 アペクシジェン， インコーポレイテッド Anti-CD40 antibodies and methods of use
DK2704743T3 (en) 2011-05-04 2020-05-25 Omeros Corp Compositions for inhibiting masp-2 dependent complement acitivation
PL2714733T4 (en) 2011-05-21 2019-08-30 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
AU2012273118A1 (en) 2011-06-20 2014-01-23 St. Louis University Targeting the neuromuscular junction for treatment
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
KR102239138B1 (en) 2011-09-30 2021-04-12 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule inducing immune response to target antigen
TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
JP6284766B2 (en) 2011-09-30 2018-02-28 中外製薬株式会社 Ion concentration-dependent binding molecule library
MX361713B (en) 2011-09-30 2018-12-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for promoting loss of antigens.
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
BR112014013081A2 (en) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha drug-containing cell vehicle for formation of an immune complex
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
EP2825553B1 (en) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
LT2825036T (en) 2012-03-16 2018-07-10 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
CN104302171B (en) 2012-03-16 2017-05-03 瑞泽恩制药公司 Non-human animals expressing PH-sensitive immunoglobulin sequences
JP6419064B2 (en) 2012-03-29 2018-11-07 ノビミューン エスアー Anti-TLR4 antibodies and uses thereof
TWI619729B (en) 2012-04-02 2018-04-01 再生元醫藥公司 Anti-hla-b*27 antibodies and uses thereof
US9605058B2 (en) 2012-05-01 2017-03-28 Glaxosmithkline Llc Antibodies against the CXC-ELR family of chemokines
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TWI766939B (en) 2012-05-30 2022-06-11 日商中外製藥股份有限公司 target tissue-specific antigen binding molecule
ES2856272T3 (en) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule to remove aggregated antigens
KR101704893B1 (en) 2012-06-15 2017-02-08 화이자 인코포레이티드 Improved antagonist antibodies against gdf-8 and uses therefor
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
EA028244B1 (en) 2012-08-13 2017-10-31 Ридженерон Фармасьютикалз, Инк. ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
MX371442B (en) 2012-08-24 2020-01-30 Chugai Pharmaceutical Co Ltd Fcyriib-specific fc region variant.
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
TWI595007B (en) 2012-09-10 2017-08-11 Neotope Biosciences Ltd Anti-mcam antibodies and associated methods of use
SI3835310T1 (en) 2012-09-13 2024-07-31 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
TW201418707A (en) 2012-09-21 2014-05-16 Alexion Pharma Inc Screening assays for complement component C5 antagonists
JP2016500704A (en) 2012-11-06 2016-01-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Compositions and methods for modulating cell signaling
ES2791183T3 (en) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anti-GDF15 antibodies
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
CA2898262A1 (en) 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
US10280215B2 (en) 2013-01-31 2019-05-07 Seoul National University R&Db Foundation Anti-C5 antibodies and methods of treating complement-related diseases
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
US9321686B2 (en) 2013-03-15 2016-04-26 Forta Corporation Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
EP2970508A4 (en) 2013-03-15 2016-12-14 Permeon Biologics Inc Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
JP2016516064A (en) 2013-03-15 2016-06-02 アムジェン インコーポレイテッド Myostatin antagonism in human subjects
US20160032014A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
ES2743216T3 (en) 2013-03-15 2020-02-18 Xencor Inc Heterodimeric proteins
CA2897334A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
CN113621057A (en) 2013-04-02 2021-11-09 中外制药株式会社 Fc region variants
WO2014182676A2 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CA2911600A1 (en) 2013-05-17 2014-11-20 Centre National De La Recherche Scientifique (Cnrs) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
AU2014273817B2 (en) 2013-05-31 2019-03-14 Zymeworks Bc Inc. Heteromultimers with reduced or silenced effector function
ES2683268T3 (en) 2013-07-25 2018-09-25 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods for using them
EP3033358A2 (en) 2013-08-14 2016-06-22 Novartis AG Methods of treating sporadic inclusion body myositis
CA2920293A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
US10208094B2 (en) 2013-09-04 2019-02-19 Protenova Co., Ltd. Multimeric immunoglobulin-binding domain
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
MX2016008098A (en) 2013-12-20 2017-01-11 Hoffmann La Roche Bispecific her2 antibodies and methods of use.
EP3100056A2 (en) 2014-01-27 2016-12-07 Novartis AG Biomarkers predictive of muscle atrophy, method and use
EP4008726A1 (en) 2014-02-20 2022-06-08 Allergan, Inc. Complement component c5 antibodies
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
TW201622746A (en) 2014-04-24 2016-07-01 諾華公司 Methods of improving or accelerating physical recovery after surgery for hip fracture
JP7037885B2 (en) 2014-06-30 2022-03-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-TNFa antibody showing pH-dependent antigen binding
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
US10307480B2 (en) 2014-11-06 2019-06-04 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
JP2017538701A (en) 2014-12-08 2017-12-28 ノバルティス アーゲー Myostatin or activin antagonist for the treatment of sarcopenia
KR101838645B1 (en) 2014-12-19 2018-03-14 추가이 세이야쿠 가부시키가이샤 Anti-c5 antibodies and methods of use
TWI779010B (en) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
CN112142844A (en) 2015-02-05 2020-12-29 中外制药株式会社 Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof
TWI805046B (en) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Use of IL-6 receptor antibody for preparing pharmaceutical composition
US20190135903A1 (en) 2015-03-31 2019-05-09 Alexion Pharmaceuticals, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
MX2017013267A (en) 2015-04-15 2018-08-15 Regeneron Pharma Methods of increasing strength and functionality with gdf8 inhibitors.
US20180311299A1 (en) 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
EP3313437A1 (en) 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
US10940126B2 (en) 2015-07-03 2021-03-09 Camilla Svensson Inhibition of IL-8 in the treatment of pain and/or bone loss
KR20230155021A (en) 2015-09-15 2023-11-09 스칼러 락, 인크. Anti-pro/latent-myostatin antibodies and uses thereof
AR105634A1 (en) 2015-09-18 2017-10-25 Chugai Pharmaceutical Co Ltd ANTIBODIES THAT JOIN IL 8 AND ITS USES
TW201718014A (en) 2015-10-12 2017-06-01 諾華公司 Use of C5 inhibitors in Transplant Associated Microangiopathy
AR107078A1 (en) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd ANTIMOSTATIN ANTIBODY, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS AS WELL AS METHODS OF USE
MA44081B1 (en) 2015-12-18 2023-11-30 Chugai Pharmaceutical Co Ltd ANTI-C5 ANTIBODIES AND METHODS OF USE THEREOF
US10233252B2 (en) 2015-12-21 2019-03-19 Wisconsin Alumni Research Foundation pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2017206069A1 (en) 2016-01-08 2018-07-19 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
EP3402816A1 (en) 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
MA53248A (en) 2016-01-25 2022-02-16 Takeda Pharmaceuticals Co PH-ENHANCED ANTI-C5 ANTIBODIES
KR20210082548A (en) 2016-06-13 2021-07-05 스칼러 락, 인크. Use of myostatin inhibitors and combination therapies
CN116769024A (en) 2016-06-14 2023-09-19 瑞泽恩制药公司 anti-C5 antibodies and uses thereof
IL300611A (en) 2016-06-17 2023-04-01 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
BR112018073628A2 (en) 2016-06-17 2019-02-26 Chugai Seiyaku Kabushiki Kaisha antimiostatin antibodies and methods of use
KR102538749B1 (en) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Composition for prophylaxis or treatment of il-8 related diseases
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
ES2947735T3 (en) 2017-01-31 2023-08-17 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of diseases related to C5
BR112019019108A2 (en) 2017-03-14 2020-04-22 Five Prime Therapeutics, Inc. antibodies, nucleic acid, compositions, cell, methods for preparing an antibody, to treat a subject with cancer, to treat an infectious disease, to treat an inflammation, to identify an ab, to improve an ab's anti-tumor efficacy, to improve the pharmacokinetics of an antibody, for selection of an antibody, to improve the effectiveness of antibodies, to isolate antibodies and to detect sight in a sample
EP3596125A1 (en) 2017-03-16 2020-01-22 Medimmune Limited Anti-par2 antibodies and uses thereof
SG11201807998WA (en) 2017-04-03 2018-12-28 Inflarx Gmbh Treatment Of Inflammatory Diseases With Inhibitors Of C5a Activity
KR20200070355A (en) 2017-10-26 2020-06-17 알렉시온 파마슈티칼스, 인코포레이티드 Dosage and administration of anti-C5 antibodies for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS)
CA3084043A1 (en) 2017-12-04 2019-06-13 Ra Pharmaceuticals, Inc. Modulators of complement activity
TWI701041B (en) 2018-08-01 2020-08-11 日商中外製藥股份有限公司 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
BR112021020204A2 (en) 2019-04-10 2021-12-07 Chugai Pharmaceutical Co Ltd Method for purifying antibody with modified fc region

Also Published As

Publication number Publication date
RU2018121428A3 (en) 2019-12-09
CA2819356C (en) 2023-01-24
TW202043266A (en) 2020-12-01
KR102568454B1 (en) 2023-08-18
KR102385507B1 (en) 2022-04-12
US20140234340A1 (en) 2014-08-21
RU2013129815A (en) 2015-01-10
EP4231014A3 (en) 2024-08-14
TWI654203B (en) 2019-03-21
JP2022105222A (en) 2022-07-12
TW201920260A (en) 2019-06-01
EP2647706A4 (en) 2015-04-22
TW201249871A (en) 2012-12-16
HK1251592A1 (en) 2019-02-01
EP2647706B1 (en) 2023-05-17
TWI812066B (en) 2023-08-11
JP2020189850A (en) 2020-11-26
RU2642318C2 (en) 2018-01-24
MX2013006109A (en) 2014-01-31
RU2757786C2 (en) 2021-10-21
MX365235B (en) 2019-05-28
RU2658504C9 (en) 2018-08-21
TWI705072B (en) 2020-09-21
JP7096863B2 (en) 2022-07-06
US20240158482A1 (en) 2024-05-16
EP4231014A2 (en) 2023-08-23
TWI761912B (en) 2022-04-21
JP2017019773A (en) 2017-01-26
JP7497388B2 (en) 2024-06-10
EP2647706A1 (en) 2013-10-09
TW202225189A (en) 2022-07-01
JP6745858B2 (en) 2020-08-26
JP6030452B2 (en) 2016-11-24
AU2011337704B2 (en) 2017-06-15
US11891434B2 (en) 2024-02-06
AU2011337704A1 (en) 2013-07-04
CN107973851A (en) 2018-05-01
RU2018121428A (en) 2019-12-09
JP6431506B2 (en) 2018-11-28
US20180258161A1 (en) 2018-09-13
JP2019048842A (en) 2019-03-28
WO2012073992A1 (en) 2012-06-07
JPWO2012073992A1 (en) 2014-05-19
KR20220045258A (en) 2022-04-12
BR112013013354A2 (en) 2020-10-06
CA2819356A1 (en) 2012-06-07
HK1258068A1 (en) 2019-11-01
CN103328632A (en) 2013-09-25
RU2658504C1 (en) 2018-06-21
MX2019001726A (en) 2019-07-18
SG190727A1 (en) 2013-07-31
TWI654204B (en) 2019-03-21
KR20130121900A (en) 2013-11-06
JP2024109896A (en) 2024-08-14
CN108715614A (en) 2018-10-30
TW201730217A (en) 2017-09-01

Similar Documents

Publication Publication Date Title
HK1251592A1 (en) Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
IL259956B (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
HRP20181355T1 (en) Bispecific antigen binding molecules
IL268886B (en) Bispecific t cell activating antigen binding molecules
HK1247938A1 (en) Generation of binding molecules
IL237985B (en) Humanized immunobinder capable of binding to an antigen of interest